Johnson & Johnson named a 2022 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list.
Innovativeness. Social Responsibility. Learn how these and other key attributes landed the company on the global corporate reputation list for the 20th year in a row and ranked the company #1 on the Pharmaceutical Industry list for the ninth consecutive year.
For more than 135 years, Johnson & Johnson has been dedicated to addressing some of the world’s toughest health challenges.
And this unwavering commitment hasn’t gone unnoticed: Fortune just ranked Johnson & Johnson as a Top 50 All-Star on its World’s Most Admired Companies list for the 20th consecutive year. For 2022, the company ranked #1 on the Pharmaceutical Industry list for the ninth year in a row and in the top 20 on the overall Top 50 All-Stars list.
To compile the list and determine the best-regarded companies in 52 industries worldwide, as well as the top 50 most admired overall, consulting firm Korn Ferry asked global executives, directors and analysts to rate enterprises in their own industry on nine criteria, including quality of the organization’s management and products as well as social responsibility.
On these factors and more, Johnson & Johnson delivered.
Values-driven work to improve health across the globe
Guided by Our Credo, Johnson & Johnson’s mission statement, the company’s enduring goal has been to change the trajectory of human health. And Johnson & Johnson has been relentlessly driving toward that goal through such efforts as its groundbreaking work to help eliminate cancer, its support of health equity solutions and its pandemic response.
For 2022, the company ranked #1 on the Pharmaceutical Industry list for the ninth year in a row, and in the top 20 on the Top 50 All-Stars list.
In 2021, Johnson & Johnson’s COVID-19 vaccine received Emergency Use Authorization from the U.S. Food and Drug Administration. That same year, the Janssen Pharmaceutical Companies of Johnson & Johnson also had two new product approvals, including one for relapsing forms of multiple sclerosis. The other, for non-small cell lung cancer for patients with a specific genetic mutation, is just one example of how the company is making progress toward its vision of a world without cancer.
Last year the company also kicked off its Health Equity Innovation Challenge to find and fast-track advances that have the potential to diminish healthcare disparities in the U.S. The Challenge follows the launch of Our Race to Health Equity, through which Johnson & Johnson announced in late 2020 that it was committing $100 million over the next five years to invest in and promote health equity solutions for Black people and other people of color in the U.S.
Another notable milestone from 2021: Johnson & Johnson released its 2020 Health for Humanity Report, which detailed its progress in meeting 17 sustainability goals by 2020 (it achieved or exceeded 16 of them) as well as strides made toward its five United Nations 2030 Sustainable Development Goals (it exceeded four of its targets). And by the year’s end, Johnson & Johnson signed a power purchase agreement that means nearly all of its sites in Europe, the United States and Canada will be powered with 100% renewable electricity by 2023—beating one of the company’s Health for Humanity 2025 Goals by two years.
Johnson & Johnson has always aimed to put a world of well within reach of everyone, everywhere. It is honored to be named one of Fortune‘s World’s Most Admired Companies once again.